Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12615000771550
Ethics application status
Approved
Date submitted
14/07/2015
Date registered
24/07/2015
Date last updated
24/07/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Adaptive Radiotherapy for Head and Neck Cancer: Feasibility and Clinical Implications
Query!
Scientific title
Effect of Adaptive Radiotherapy on the dose to Organs at Risk and Target Volumes in patients with Locally Advanced Head and Neck Cancer
Query!
Secondary ID [1]
287030
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ART Study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Head and Neck Cancer
295496
0
Query!
Condition category
Condition code
Cancer
295753
295753
0
0
Query!
Head and neck
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Adaptive radiotherapy involves re-planning the radiation treatment during the course of treatment to account for changes in shape due to tumour shrinkage and patient weight loss. This can potentially reduce the radiation dose received by normal structures (particularly the parotid salivary glands), and increase the dose received by the target volume.
Patients will undergo standard curative-intent definitive radiotherapy (70Gy in 35 fractions, 2Gy per fraction, 1 fraction per day delivered 5 days per week for overall duration of 7 weeks). The participants will continue with this dose schedule for the whole course of treatment. At 3 and 5 weeks of treatment they will undergo both a repeat radiotherapy planning CT and repeat PET-CT. The repeat planning CT will be loaded on to the radiotherapy treatment planning system. The patient's initial RT plan will be overlaid on to this and re-calculated by the treatment planning system to give the new expected dose distribution on the patient's altered anatomy. The PI will then manually re-contour all the target volumes and normal structures on the repeat scans to create a new RT plan. We will then compare the dose distribution between the original plan and the re-contoured plan. to determine whether adaptive re-planning can reduce the dose to organs at risk or improve the dose to the target volume.
The participants will continue with treatment using their original radiotherapy plan unless the treating radiation oncologist deems it necessary to alter the treatment volumes (current standard treatment).
We will also assess whether the added workload associated with adaptive replanning is feasible in our department.
Query!
Intervention code [1]
292238
0
Treatment: Other
Query!
Comparator / control treatment
There is no control arm in this study but patients will act as their own control. The standard radiotherapy plan (control) will be compared to the adaptive plan (intervention) in each patient.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
295467
0
Dose to organs at risk (salivary glands, mandible, spinal cord) as predicted using the radiotherapy treatment planning system and dose accumulation method for the adaptive plans.
Query!
Assessment method [1]
295467
0
Query!
Timepoint [1]
295467
0
On completion of radiotherapy treatment, approximately 7 weeks.
Query!
Primary outcome [2]
295614
0
Dose to Planning Target Volume as predicted using the radiotherapy treatment planning system and dose accumulation method for the adaptive plans.
The maximum dose, minimum dose, mean dose, D98% (dose to 98% of the volume), D2% (dose to 2% of the volume) and a dose-volume histogram are automatically calculated and recorded by the radiotherapy treatment planning system from the radiotherapy planning CT.
Query!
Assessment method [2]
295614
0
Query!
Timepoint [2]
295614
0
On completion of radiotherapy treatment, approximately 7 weeks.
Query!
Secondary outcome [1]
315643
0
Time (hours) taken for all re-planning.
The time taken for re-contouring will be recorded for each participant by the PI performing the contouring, and an estimate of the time taken for the radiation therapists to re-plan the treatment will be added to this for each re-plan.
Query!
Assessment method [1]
315643
0
Query!
Timepoint [1]
315643
0
On completion of radiotherapy treatment (approximately 7 weeks)
Query!
Eligibility
Key inclusion criteria
- Age 18 years or above
- Histologically proven squamous cell carcinoma of the head and neck region (oropharynx, nasopharynx, hypopharynx, larynx)
- Locally advanced disease (AJCC Stage III/IV)
- Multidisciplinary decision to treat with curative intent definitive radiation or chemoradiation using Image-guided IMRT/VMAT
- ECOG 0-2
- Able to give informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Definitive surgery to primary tumour or nodal disease
- Neoadjuvant chemotherapy
- Prior radiotherapy or chemotherapy
- Previous malignancy (except treated cutaneous skin cancers)
- Pregnant or breastfeeding women
- Both parotid glands entirely within the target volume (unable to achieve parotid sparing)
- Contraindications to radiotherapy (e.g. radiosensitivity syndromes)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
3/08/2015
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
3995
0
Fiona Stanley Hospital - Murdoch
Query!
Funding & Sponsors
Funding source category [1]
291580
0
Government body
Query!
Name [1]
291580
0
WA Cancer and Palliative Care Network Cancer Fellowship
Query!
Address [1]
291580
0
Ground Floor, C Block 189 Royal Street
East Perth WA 6004
Query!
Country [1]
291580
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Susan Mincham
Query!
Address
Radiation Oncology
Fiona Stanley Hospital
102-118 Murdoch Drive
Murdoch WA 6150
Query!
Country
Australia
Query!
Secondary sponsor category [1]
290252
0
None
Query!
Name [1]
290252
0
Query!
Address [1]
290252
0
Query!
Country [1]
290252
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
293115
0
South Metropolitan Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
293115
0
Office 212, Level 2, Southern Research Facility Fiona Stanley Hospital 102-118 Murdoch Drive Murdoch WA 6150
Query!
Ethics committee country [1]
293115
0
Australia
Query!
Date submitted for ethics approval [1]
293115
0
05/05/2015
Query!
Approval date [1]
293115
0
25/06/2015
Query!
Ethics approval number [1]
293115
0
15/33
Query!
Summary
Brief summary
This project aims to evaluate whether a protocol of adaptive radiotherapy (ART) for Head and Neck cancer patients can provide significant reduction in radiotherapy dose to critical structures, particularly the parotid salivary glands, aiming to potentially reduce the long term side effects of radiotherapy (particularly dry mouth). Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with locally advanced head and neck cancer for which you plan to undergo curative-intent definitive radiotherapy. Study details All participants in this study will receive standard radiotherapy treatment (5 days a week for 7 weeks) as prescribed by the treating Radiation Oncologist. At 3 weeks and 5 weeks participants will have a repeat non-contrast planning CT scan plus repeat PET scan. We then overlay the initial radiotherapy plan on to the new CT dataset to determine if there are significant shape changes, whether the critical structures are receiving too much dose, or if the target volume (the tumour) is receiving too little dose. The participant’s radiotherapy plan will only be altered if there are unacceptable areas of radiotherapy over or under-dosage according to the discretion of the treating radiation oncologist. All participants will have a new radiotherapy plan created using their repeat scans. These plans will be run through our treatment planning computers to model the dose distribution on the new CT datasets. We will then compare the dose received by the normal structures and the tumour using this "adaptive approach" with the expected doses if no changes are made to the initial plan. This will give us a measure of the benefit of ART. We will also record how much time each re-planning takes to evaluate whether an adaptive approach is feasible in a real world clinical setting.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
58538
0
Dr Susan Mincham
Query!
Address
58538
0
Radiation Oncology (Genesis Cancer Care)
Fiona Stanley Hospital
102-118 Murdoch Drive
Murdoch WA 6150
Query!
Country
58538
0
Australia
Query!
Phone
58538
0
+61 8 61524954
Query!
Fax
58538
0
Query!
Email
58538
0
[email protected]
Query!
Contact person for public queries
Name
58539
0
Susan Mincham
Query!
Address
58539
0
Radiation Oncology (Genesis Cancer Care)
Fiona Stanley Hospital
102-118 Murdoch Drive
Murdoch WA 6150
Query!
Country
58539
0
Australia
Query!
Phone
58539
0
+61 8 61524954
Query!
Fax
58539
0
Query!
Email
58539
0
[email protected]
Query!
Contact person for scientific queries
Name
58540
0
Susan Mincham
Query!
Address
58540
0
Radiation Oncology (Genesis Cancer Care)
Fiona Stanley Hospital
102-118 Murdoch Drive
Murdoch WA 6150
Query!
Country
58540
0
Australia
Query!
Phone
58540
0
+61 8 61524954
Query!
Fax
58540
0
Query!
Email
58540
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF